Pulse Biosciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PLSE and other ETFs, options, and stocks.

About PLSE

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. 

CEO
Paul A. LaViolette
CEOPaul A. LaViolette
Employees
116
Employees116
Headquarters
Miami, Florida
HeadquartersMiami, Florida
Founded
2014
Founded2014
Employees
116
Employees116

PLSE Key Statistics

Market cap
1.53B
Market cap1.53B
Price-Earnings ratio
-20.67
Price-Earnings ratio-20.67
Dividend yield
Dividend yield
Average volume
281.97K
Average volume281.97K
High today
$22.64
High today$22.64
Low today
$21.29
Low today$21.29
Open price
$22.13
Open price$22.13
Volume
28.85K
Volume28.85K
52 Week high
$26.30
52 Week high$26.30
52 Week low
$12.56
52 Week low$12.56

Stock Snapshot

Pulse Biosciences(PLSE) stock is priced at $22.44, giving the company a market capitalization of 1.53B. It carries a P/E multiple of -20.67.

On 2026-03-18, Pulse Biosciences(PLSE) stock moved within a range of $21.29 to $22.64. With shares now at $22.44, the stock is trading +5.4% above its intraday low and -0.9% below the session's peak.

Trading activity shows a volume of 28.85K, compared to an average daily volume of 281.97K.

The stock's 52-week range extends from a low of $12.56 to a high of $26.30.

The stock's 52-week range extends from a low of $12.56 to a high of $26.30.

PLSE News

Simply Wall St 13h
Pulse Biosciences Is Up 14.8% After Refocusing On nPulse AFib Catheter Platform - Has The Bull Case Changed?

Pulse Biosciences, Inc. recently shifted its capital allocation to prioritize and accelerate development of its nPulse Cardiac Catheter Ablation System after re...

Pulse Biosciences Is Up 14.8% After Refocusing On nPulse AFib Catheter Platform - Has The Bull Case Changed?
TipRanks 6d
Pulse Biosciences Launches Thyroid Cancer Feasibility Study

Pulse Biosciences ( (PLSE) ) has shared an announcement. On March 12, 2026, Pulse Biosciences announced that the first patients were enrolled in a multicenter,...

People also own

Based on the portfolios of people who own PLSE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.